Intraventricular immunotoxin therapy for leptomeningeal neoplasia

Neurosurgery

Volumn 41, Issue 5, 1997, Pages 1039-1051

  Laske, Douglas W ^a   Muraszko, Karin M ^b   Oldfield, Edward H ^c   Devroom, Hetty L ^d   Sung, Cynthia ^a   Dedrick, Robert L ^e   Simon, Theodore R ^a   Colandrea, Jean ^b   Copeland, Christie ^c   Katz, David ^d   Greenfield, Larry ^a   Groves, Eric S ^e   Houston, L L ^a   Youle, Richard J ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c Laboratory of Mathematical Biology   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antibody; Cancer; Cerebrospinal fluid; Pharmacokinetics; Ricin toxin

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLUOROURACIL; IMMUNOTOXIN; INTERLEUKIN 2; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; PENTETATE TECHNETIUM TC 99M; PREDNISONE; RICIN A; STEROID; TAMOXIFEN; THIOTEPA; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER IMMUNOTHERAPY; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID DRAINAGE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DEGRADATION; HEADACHE AND FACIAL PAIN; HUMAN; IMMUNOBLOTTING; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LEPTOMENINX; MELANOMA; MENINGIOMA; PRIORITY JOURNAL; VOMITING;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CEREBRAL VENTRICLES; FEMALE; HALF-LIFE; HUMANS; IMMUNOTOXINS; INFUSIONS, PARENTERAL; MELANOMA; MENINGEAL NEOPLASMS; METABOLIC CLEARANCE RATE; MICE; MIDDLE AGED; PILOT PROJECTS; RECEPTORS, TRANSFERRIN; RECOMBINANT PROTEINS; RICIN; SPINAL CORD NEOPLASMS; TECHNETIUM TC 99M PENTETATE;

EID: 0030712969     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199711000-00005     Document Type: Article

References (72)

1. Adams JH, Duchen LW (eds): Grccnfield's Nenropathology. New York, Oxford University Press, 1992, ed 5.
2. Aisner ], Ostrow S, Govindan S, Wiernik PH: Leptomeningeal carcinomatosis in small cell carcinoma of the lung. Med Pediatr Oncol 9:47-59, 1981.
3. Angelova-Gateva P: Iron transferrin receptors in rat and human cerebrum. Agressologie 21:27-30, 1980.
4. Bass NH, Lundborg P: Postnatal development of bulk flow in the cerebrospinal fluid system of the albino rat: Clearance of carboxyl-[14C]inulin after intrathecal infusion. Brain Res 52:323-332, 1973.
5. Bates SE, Longo DL: Use of serum tumor markers in cancer diagnosis and management. Semin Oncol 14:102-138, 1987.
6. Bigner SH, Johnston WW: The cytopathology of cerebrospinal fluid: Part II-Metastatic carcinomatosis and primary central nervous system neoplasms. Acta Cytol 25:461-479, 1981.
7. Björn MJ, Ring D, Frankel A: Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res 45:1214-1221, 1985.
8. Blasberg RG, Patlak CS, Shapiro WR: Distribution of methotrexate in the cerebrospinal fluid and brain after intraventricular administration. Cancer Treat Rep 61:633-641, 1977.
9. Bleyer WA: Current status of intrathecal chemotherapy for human meningeal neoplasms. Natl Cancer Inst Monogr 46:171-178, 1977.
10. Bunn PA, Schein PS: Meningeal involvement in lymphoma. N Engl J Med 290:517, 1974 (letter).
11. Collins JM, Riccardi R, Trown P, O'Neill D, Poplack DG: Plasma and cerebrospinal fluid pharmacokinetics of recombinant interferon alpha A in monkeys: Comparison of intravenous, intramuscular, and intraventricular delivery. Cancer Drug Deliv 2:247253, 1985.
12. Connor Jr., Fine RE: The distribution of transferrin immunoreactivity in the rat central nervous system. Brain Res 368:319-328, 1986.
13. Davson H: Physiology of the Cerebrospinal Fluid. London, J. & A. Churchill, Ltd., 1967.
14. Dedrick RL, Flessner MF: Pharmacokinetic considerations on monoclonal antibodies, in Mitchell MS (ed): Immunity to Cancer 11. New York, Alan R. Liss, 1989, pp 429-138.
15. Faulk WP, Hsi BL, Stevens PL: Transferrin and transferrin receptors in carcinoma of the breast. Lancet 2:390-392, 1980.
16. Fodstad O, Kvalheim G, Godal A, Lotsberg J, Aamdal S, Host H, Pihl A: Phase I study of the plant protein ricin. Cancer Res 44:862-665, 1984.
17. Galbraith GMP, Galbraith RM, Faulk WP: Transferrin binding by human lymphoblastoid cell lines and other transformed cells. Cell Immunol 49:215-222, 1980.
18. Gatter KC, Brown G, Trowbridge IS, Woolston RE, Mason DY: Transferrin receptors in human tissues: Their distribution and possible clinical relevance. J Clin Pathol 36:539-545, 1983.
19. Giannone L, Greco FA, Hainsworth JD: Combination intraventricular chemotherapy for meningeal neoplnsia. J Clin Oncol 4:68-74, 1986.
20. Gilliland DG, Sleplewski Z, Collier RJ, Mitchell KF, Chang TH, Koprowski H: Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sei U S A 77:4539-4543, 1980.
21. Gonzalez-Vitale JC, Garcia-Bunuel R: Meningeal carcinomatosis. Cancer 37:2906-2911, 1976.
22. Grain GO, Karr JP: Diffuse leptomeningeal carcinomatosis: Clinical and pathologie characteristics. Neurology 5:706-722, 1955.
23. Gregg EO, Bridges SH, Youle RJ, Longo DL, Houston LL, Glennie MJ, Stevenson FK, Green I: Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia. J Immunol 138:4502-4508, 1987.
24. Gutin PH, Weiss HD, Wiernik PH, Walker MD: Intrathecal N, N′, N″-triethylene thiophosphoramide (thio-tepa) in the treatment of malignant meningeal disease (phase I-II study). Cancer 38:14711475, 1976.
25. Hertler AA, Schlossman DM, Borowitz MJ, Poplack DG, Frankel AE: An immunotoxin for the treatment of T-cell acute lymphoblastic leukemic meningitis: Studies in rhesus monkeys. Cancer Immunol Immunother 28:59-66, 1989.
26. Hill JM, Ruff MR, Weber RJ, Pert CB: Transferrin receptors in rat brain: Neuropeptide-like pattern and relationship to iron distribution. Proc Natl Acad Sei U S A 82:4554-4557, 1985.
27. lierai O, Laske DW, Walbridge S, Muraszko KM, Oldfield EH, Youle RJ: Neurotoxicity of immunotoxins. Mol Chem Neuropathol 21:379-386, 1994.
28. jeffries WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY: Transferrin receptor on endothelium of brain capillaries. Nature 312:162-163, 1984.
29. Johnson VG, Wrobel C, Wilson D, Zovickian J, Greenfield L, Oldfield EH, Youle RJ: Improved tumor specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia. J Neurosurg 70:240-248, 1989.
30. Karnofsky DA, Burchenal JH, Armistead GC Jr., Southam CM, Bernstein JL, Craver LF, Rhoads CP: Triethylene melamine in the treatment of neoplastic disease. Arch Intern Med 87:477-516, 1951.
31. Krolick KA, Villemez C, Isakson P, Uhr JW, Vitetta ES: Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc Natl Acad Sei U S A 77:5419-5423, 1980.
32. Larrick JW, Cresswell P: Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J Supramol Struct 11:579-586, 1979.
33. Lashford LS, Davies AG, Richardson RB, Bourne SP, Bullimore JA, Eckert H, Kemshead JT, Coakham HB: A pilot study of 131I monoclonal antibodies in the therapy of leptomeningeal tumors. Cancer 61:857-868, 1988.
34. Laurent G, Pris J, Farcet JP, Carayon P, Blythman H, Casellas P, Poncelet P, Jansen FK: Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood 76:1680-1687, 1986.
35. Levin VA, Chamberlain M, Silver P, Rodriguez L, Prados M: Phase I/II study of intraventricular and intrathecal ACNU for leptomeningeal neoplasia. Cancer Chemother Pharmacol 23:301-307, 1989.
36. Mann JD, Butler AB, Johnson RN, Bass NH: Clearance of macromolecular and particulate substances from the cerebrospinal fluid system of the rat. J Neurosurg 50:343-348, 1979.
37. Messert B, Rieder J: RISA cisternography: Study of spinal fluid changes associated with intrathecal RISA injection. Neurology 22:789-792, 1972.
38. Muraszko K, Sung C, Walbridge S, Greenfield L, Dedrick RL, Oldfield EH, Youle RJ: Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents. Cancer Res 53:3752-3757, 1993.
39. Nugent JL, Bunn PA, Mathews MJ, Ihde DC, Cohen MH, Gazdar A, Minna JD: CNS métastases in small cell bronchogenic carcinoma: Increasing frequency and changing patterns with lengthening survival. Cancer 44:1885-1893, 1979.
40. Olsnes S, Pihl A: Different biological properties of the two constituent peptide chains of ricin, a toxic protein inhibiting protein synthesis. Biochemistry 12:3121-3126, 1973.
41. Olson ME, Chernik NL, Posner JB: Infiltration of the leptomeninges by systemic cancer: A clinical and pathologic study. Arch Neurol 30:122-137, 1974.
42. Ongerboer de Visser BWO, Somers R, Nooyen WH, van Heerde P, Hart AA, McVie JG: Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33: 1565-1572, 1983.
43. Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW Jr., Longo DL, Gould B, Frankel A, McClay EF, Howell S, Reed E, Willingham C, Fitzgerald DJ, Pastan I: Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. J Clin Oncol 9:2095-2103, 1991.
44. Papadopoulos NM: Clinical applications of lactate dehydrogenase isoenzymes. Ann Clin Lab Sei 7:506-510, 1977.
45. Pastan IH, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Wang QC, Pai LH, Herndon ], Bigner DD: Intrathecal administration of single-chain immunoloxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proc Natl Acad USA 92:2765-2769, 1995.
46. Rapoport SI: Passage of proteins from blood to cerebrospinal fluid, in Rapoport SI (ed): The Neurobiology of Cerebrospinal Fluid. New York, Plenum Press, 1983.
47. Riccardi R, Holcenberg JS, Glaubiger DL, Wood JH, Poplack DG: L-Asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 41: 4554-4558, 1981.
48. Richardson EP Jr.: Neurologic effects of cancer, in Holland JF, Frei E (eds): Cancer Medicine. Philadelphia, Lea & Febiger, 1973, pp 1057-1067.
49. Riedel CJ, Muraszko KM, Youle RJ: Diphtheria toxin mutant selectively kills cerebellar Purkinje neurons. Proc Natl Acad Sei USA 87:5051-5055, 1990.
50. Rybak SM, Youle RJ: Clinical use of immunotoxins: Monoclonal antibodies conjugated to protein toxins. Immunol Allergy Clin N Am 11:359-380, 1991.
51. Shindelman AE, Ortmeyer AE, Sussman HH: Demonstration of the transferrin receptor in human breast cancer tissue: Potential marker for identifying dividing cells. Int J Cancer 27:329-334, 1981.
52. Silverberg E: Cancer statistics. CA Cancer J Clin 39:3-20, 1989.
53. Skullerud K, Halvorsen K: Encephalomyelopathy following intrathecal methotrexate treatment in a child with acute leukemia. Cancer 42:1211-1215, 1978.
54. Sondak V, Deckers PJ, Feller JH, Mozden PJ: Leptomeningeal spread of breast cancer. Cancer 48:395-399, 1981.
55. Sorensen SC, Eagan RT, Scott M: Meningeal carcinomatosis in patients with primary breast or lung cancer. Mayo Clinic Proc 59:91-92, 1984.
56. Spitler LE, del Rio M, Khentigan A, Wedel NI, Brophy NA, Miller LL, Harkonen WS, Rosendorf LL, Lee HM, Mischak RP, Kawahata RT, Stoudemire JB, Fradkin LB, Bautista EE, Scannen PJ: Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res 47:1717-1723, 1987.
57. Trowbridge IS, Domingo DL: Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature 294:171-173, 1981.
58. Trowbridge IS, Omary MB: Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc Natl Acad Sei U S A 78:3039-3043, 1981.
59. Trowbridge IS, Newman RA, Domingo DL, Sauvage C: Transferrin receptors: Structure and function. Biochem Pharmacol 33: 925-932, 1984.
60. Vitetta ES, Fulton RJ, May RD, Till M, Uhr JW: Redesigning nature's poisons to create anti-tumor reagents. Science 238:1098-1104, 1987.
61. Wallace RM, Bigner SH, Johnston WW: Metastatic breast carcinoma in cerebrospinal fluid. Acta Cytol 26:787-792, 1982.
62. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal métastases from solid tumors. Cancer 49:759-772, 1982.
63. Weiner LM, O'Dwyer J, Kitson J, Comis RL, Frankel AE, Bauer RJ, Konrad MS, Groves ES: Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate. Cancer Res 49:4062-4067, 1989.
64. Whitmore EL, Hochberg F, Wolfson L, Royalty J, Taft PD: Quantitative cytocentrifugation in the evaluation of cerebrospinal fluid. Acta Cytol 26:847-850, 1982.
65. Wood JH: Physiology, pharmacology and dynamics of cerebrospinal fluid, in Wood JH (ed): Nenrobiology of Cerebrospinal Fluid. New York, Plenum Publishing, 1980, pp 1-16.
66. Yap HY, Yap BS, Rasmussen S, Levens ME, Hortobagyi GN, Blumenschein GR: Treatment for meningeal carcinomatosis in breast cancer. Cancer 49:219-222, 1982.
67. Youle RJ, Colombatti M: Monoclonal antibodies linked to toxic proteins for bone marrow transplantation and cancer therapy, in Roth JA (ed): Monoclonal Antibodies in Cancer: Advances in Diagnosis and Treatment. New York, Futura Publishing Co., 1986, pp 173-213.
68. Youle RJ, Neville DM Jr.: Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin. Proc Natl Acad Sei U S A 77:5483-5486, 1980.
69. Youle RJ, Neville DM Jr.: Kinetics of protein synthesis inactivation by ricin anti-Thy 1.1 monoclonal antibody hybrids: Role of the ricin B subunit demonstrated by reconstitution. J Biol Chem 257:1598-1601, 1982.
70. Zondag HA, Klein F: Clinical application of lactate dehydrogenase isoenzymes: Alterations in malignancy. Ann N Y Acad Sei 151:578-586, 1968.
71. Zovickian JG, Youle RJ: Efficacy of intrathecal immunotoxin therapy in an animal model of leptomeningeal neoplasia. J Neurosurg 68:767-774, 1988.
72. Zovickian JG, Johnson VG, Youle RJ: Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. J Neurosurg 66:850-861, 1987.